| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,610,000 |
| Market
Cap: |
326.96(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.6 - $8.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MeiraGTx Holdings is a clinical stage gene therapy company with six programs in clinical development and a pipeline of preclinical and research programs. Co.'s focus is on three areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Co.'s product candidates include: AAV-RPE65 for the treatment of retinal dystrophy associated with mutations in the RPE65 gene; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of Leber congenital amaurosis 4; as well as AAV-RDH12 for the treatment of RDH12 Mutation-Associated Retinal Dystrophy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
4,353,826 |
| Total Buy Value |
$0 |
$0 |
$0 |
$25,047,440 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Forbes Alexandria |
PRESIDENT & CEO |
• • – |
2024-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
125,000 |
1,404,489 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2024-01-07 |
4 |
D |
$6.30 |
$349,776 |
D/D |
(55,520) |
824,474 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2024-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
105,000 |
879,994 |
|
- |
|
| Zeldin Robert K |
CHIEF MEDICAL OFFICER |
• – – |
2024-01-07 |
4 |
D |
$6.30 |
$116,594 |
D/D |
(18,507) |
66,980 |
|
- |
|
| Zeldin Robert K |
CHIEF MEDICAL OFFICER |
• – – |
2024-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
85,487 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
10% Owner |
– – • |
2023-09-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,641,064 |
|
18% |
|
| Johnson & Johnson Development Corp Et Al |
10% Owner |
– – • |
2023-09-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,641,064) |
0 |
|
- |
|
| Harris Keith R. |
|
– • – |
2023-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Indyk Martin |
|
– • – |
2023-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-05-05 |
4 |
B |
$5.75 |
$25,000,000 |
I/I |
4,347,826 |
11,281,103 |
1.5 |
-8% |
|
| Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
• – – |
2023-01-14 |
4 |
D |
$6.99 |
$36,963 |
D/D |
(5,288) |
5,712 |
|
- |
|
| Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
• – – |
2023-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
11,000 |
|
- |
|
| Naylor Stuart |
CHIEF DEV. OFFICER |
• – – |
2023-01-14 |
4 |
D |
$6.99 |
$156,052 |
D/D |
(22,325) |
490,792 |
|
- |
|
| Naylor Stuart |
CHIEF DEV. OFFICER |
• – – |
2023-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,500 |
513,117 |
|
- |
|
| Zeldin Robert K |
CHIEF MEDICAL OFFICER |
• – – |
2023-01-14 |
4 |
D |
$6.99 |
$206,296 |
D/D |
(29,513) |
50,487 |
|
- |
|
| Zeldin Robert K |
CHIEF MEDICAL OFFICER |
• – – |
2023-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,000 |
80,000 |
|
- |
|
| Forbes Alexandria |
PRESIDENT & CEO |
• • – |
2023-01-14 |
4 |
D |
$6.99 |
$221,765 |
D/D |
(31,726) |
1,106,450 |
|
- |
|
| Forbes Alexandria |
PRESIDENT & CEO |
• • – |
2023-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
60,000 |
1,138,176 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2023-01-14 |
4 |
D |
$6.99 |
$184,802 |
D/D |
(26,438) |
774,994 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2023-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
801,432 |
|
- |
|
| Naylor Stuart |
CHIEF DEV. OFFICER |
• – – |
2023-01-08 |
4 |
D |
$6.60 |
$124,080 |
D/D |
(18,800) |
465,617 |
|
- |
|
| Naylor Stuart |
CHIEF DEV. OFFICER |
• – – |
2023-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,000 |
484,417 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2023-01-08 |
4 |
D |
$6.60 |
$130,871 |
D/D |
(19,829) |
751,432 |
|
- |
|
| Giroux Richard |
CFO & COO |
• – – |
2023-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
771,261 |
|
- |
|
| Forbes Alexandria |
PRESIDENT & CEO |
• • – |
2023-01-08 |
4 |
D |
$6.60 |
$170,128 |
D/D |
(25,777) |
1,078,176 |
|
- |
|
130 Records found
|
|
Page 2 of 6 |
|
|
0.07 (1.38%) 
